Controversies in Allergy: Chemotherapy Reactions, Desensitize, or Delabel?

David I Hong; Ricardo Madrigal-Burgaleta; Aleena Banerji; Mariana Castells; Emilio Alvarez-Cuesta

doi:10.1016/j.jaip.2020.08.005

Controversies in Allergy: Chemotherapy Reactions, Desensitize, or Delabel?

J Allergy Clin Immunol Pract. 2020 Oct;8(9):2907-2915.e1. doi: 10.1016/j.jaip.2020.08.005. Epub 2020 Aug 14.

Authors

David I Hong¹, Ricardo Madrigal-Burgaleta², Aleena Banerji³, Mariana Castells¹, Emilio Alvarez-Cuesta⁴

Affiliations

¹ Brigham & Women's Hospital, Department of Medicine, Division of Allergy and Clinical Immunology, Boston, Mass.
² Allergy & Severe Asthma Service, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. Electronic address: ricardo.madrigal.md.phd@gmail.com.
³ Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Boston, Mass.
⁴ Division of Allergy, Ramon y Cajal University Hospital, Madrid, Spain.

PMID: 32805455
DOI: 10.1016/j.jaip.2020.08.005

No abstract available

Keywords: Biological agents; Chemotherapy; Delabeling; Drug allergy; Drug challenge; Drug desensitization; Drug provocation tests; Risk stratification; Skin test.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / therapeutic use
Drug Hypersensitivity* / drug therapy
Drug Hypersensitivity* / therapy
Humans
Skin Tests

Substances

Anti-Bacterial Agents